Skip to main content
Article thumbnail
Location of Repository

Oral transmucosal fentanyl citrate in cancer pain management: a practical application of nanotechnology

By Kyriaki Mystakidou, Eleni Tsilika, Marinos Tsiatas and Lambros Vlahos


Pain is experienced by most cancer patients and represents an important issue in the clinical setting. Breakthrough pain is a transitory flare of pain that occurs in most cancer patients on a background of otherwise controlled persistent pain. Treatment of breakthrough pain is a challenging phenomenon. Oral transmucosal fentanyl citrate (OTFC; Actiq®, Cephalon, UK), a new opioid formulation with a unique delivery system, utilizing the advantages that nanotechnology offers, reflects the characteristics of breakthrough pain (rapid onset of action and short duration), which makes it an effective treatment to cancer patients who are already receiving opioids and continue to experience such flares of pain. Oral transmucosal fentanyl citrate is specifically developed and approved for the management of breakthrough pain in cancer patients and it has the potential to be a useful tool for clinicians

Topics: Review
Publisher: Dove Medical Press
OAI identifier:
Provided by: PubMed Central

Suggested articles


  1. (2003). A pharmacokinetic study to compare two simultaneous 400 microg doses with a single 800 microg dose of oral transmucosal fentanyl citrate.
  2. (2003). Actiq® Summary of Product Characteristics.
  3. (2001). Breakthrough cancer pain: a randomized trial comparing oral transmucosal fentanyl citrate (OTFC) and morphine sulfate immediate release (MSIR).
  4. (2003). Cancer breakthrough pain characteristics and responses to treatment at a VA medical center.
  5. (1983). Clinical pharmacokinetics of fentanyl and its newer derivatives.
  6. (1998). Dose titration, multicenter study of oral transmucosal fentanyl citrate for the treatment of breakthrough pain in cancer patients using transdermal fentanyl for persistent pain.
  7. (2006). Emerging implications of nanotechnology on cancer diagnostics and therapeutics.
  8. (2005). Oral transmucosal fentanyl citrate for the treatment of breakthrough pain in cancer patients: an overview of its pharmacological and clinical characteristics. Am J Hosp Palliat Care,
  9. (2004). Oral transmucosal fentanyl citrate in the outpatient management of severe cancer pain crises: a retrospective case series.
  10. (2002). Oral transmucosal fentanyl citrate: a novel agent for breakthrough pain related to cancer. Expert Rev Neurotherapeutics,
  11. (2006). Oral transmucosal fentanyl citrate: overview of pharmacological and clinical characteristics.
  12. (1998). Oral transmucosal fentanyl citrate: Randomised, double-blinded, placebo-controlled trial for the treatment of breakthrough pain in cancer patients.
  13. (1982). Plasma protein binding and distribution of fentanyl, sufentanil, afentanil and lofentanil in blood. Arch Int Pharmacodyn Ther,
  14. (1982). Stress-induced plasma betaendorphin immunorectivity may predict postoperative morphine usage. Psychiatry Res,
  15. (2006). The performance of nanocarriers for transmucosal drug delivery. Expert Opin Drug Deliv,
  16. (1982). The prevalence and severity of pain in cancer.
  17. (1983). Ventilatory depression related to plasma fentanyl concentrations during and after anesthesia in humans. Anesth Analg,

To submit an update or takedown request for this paper, please submit an Update/Correction/Removal Request.